{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:30:59Z","timestamp":1697419859019},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1038\/sj.ijo.0803084","type":"journal-article","created":{"date-parts":[[2006,11,2]],"date-time":"2006-11-02T10:46:46Z","timestamp":1162464406000},"page":"S62-S65","source":"Crossref","is-referenced-by-count":8,"title":["New drug policy in childhood obesity"],"prefix":"10.1038","volume":"29","author":[{"given":"D","family":"Moln\u00e1r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,9,22]]},"reference":[{"key":"BF0803084_CR1","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1001\/jama.288.14.1728","volume":"288","author":"CL Ogden","year":"2002","unstructured":"Ogden CL, Flegal KM, Carroll MD, Johnson CL . Prevalence and trends in overweight among US children and adolescents, 1999\u20132000. JAMA 2002; 288: 1728\u20131732.","journal-title":"JAMA"},{"key":"BF0803084_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1753-6405.2001.tb01840.x","volume":"25","author":"ML Booth","year":"2001","unstructured":"Booth ML, Wake M, Armstrong T, Chey T, Hesketh K, Mathur S . The epidemiology of overweight and obesity among Australian children and adolescents, 1995\u201397. Aust NZ J Public Health 2001; 25: 162\u2013169.","journal-title":"Aust NZ J Public Health"},{"key":"BF0803084_CR3","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.ijo.0802945","volume":"29","author":"DC Watkins","year":"2005","unstructured":"Watkins DC, Murray LJ, McCarron P, Boreham CAG, Cran GW, Young IS, McGartland C, Robson PJ, Savage JM . Ten-year trends for fatness in Northern Irish adolescents: the Young Hearts Projects\u2014repeat cross-sectional study. Int J Obes Relat Metab Disord 2005; 29: 579\u2013585.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0803084_CR4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/03014460400027425","volume":"32","author":"FH Al-Haddad","year":"2005","unstructured":"Al-Haddad FH, Little BB, Abdul Ghafoor AG . Childhood obesity in United Arab Emirates schoolchildren: a national study. Ann Hum Biol 2005; 32: 72\u201379.","journal-title":"Ann Hum Biol"},{"key":"BF0803084_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/j.1550-8528.1995.tb00170.x","volume":"3","author":"LH Epstein","year":"1995","unstructured":"Epstein LH, Valoski AM, Kalarchian MA, McCurley J . Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res 1995; 3: 411\u2013417.","journal-title":"Obes Res"},{"key":"BF0803084_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1037\/0278-6133.13.5.373","volume":"13","author":"LH Epstein","year":"1994","unstructured":"Epstein LH, Valoski AM, Wing RR, McCurley J . Ten-yer outcomes of behavioural family-based treatment for childhood obesity. Health Psychol 1994; 13: 373\u2013383.","journal-title":"Health Psychol"},{"key":"BF0803084_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/oxfordjournals.bmb.a011620","volume":"53","author":"N Finer","year":"1997","unstructured":"Finer N . Present and future pharmacologic approaches. Brit Med Bull 1997; 53: 409\u2013432.","journal-title":"Brit Med Bull"},{"issue":"Suppl 4","key":"BF0803084_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/j.1550-8528.1995.tb00227.x","volume":"3","author":"DH Ryan","year":"1995","unstructured":"Ryan DH, Kaiser P, Bray GA . Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 (Suppl 4): 553\u2013559.","journal-title":"Obes Res"},{"key":"BF0803084_CR9","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","volume":"356","author":"WTP James","year":"2000","unstructured":"James WTP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, VanGaal LF . Effect of Sibutramine on weight maintenance after weight loss: a randimized trial. Lancet 2000; 356: 2119\u20132125.","journal-title":"Lancet"},{"key":"BF0803084_CR10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","volume":"286","author":"A Wirth","year":"2001","unstructured":"Wirth A, Krause J . Long-term weight loss with sibutramine. JAMA 2001; 286: 1331\u20131339.","journal-title":"JAMA"},{"key":"BF0803084_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1067\/mhj.2001.117510","volume":"142","author":"CA Dujovne","year":"2001","unstructured":"Dujovne CA, Zavoral JH, Rowe E, Memdel CM . Effects of sibutramine on body weight and serum lipids. Am Heart J 2001; 142: 489\u2013497.","journal-title":"Am Heart J"},{"key":"BF0803084_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","volume":"2","author":"N Finer","year":"2000","unstructured":"Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J . Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo controlled study. Diabet Obes Metab 2000; 2: 105\u2013112.","journal-title":"Diabet Obes Metab"},{"key":"BF0803084_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/oby.2003.152","volume":"11","author":"SH Kim","year":"2003","unstructured":"Kim SH, Lee YM, Jee SH, Nam CM . Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116\u20131123.","journal-title":"Obes Res"},{"key":"BF0803084_CR14","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1001\/jama.289.14.1805","volume":"289","author":"RI Berkowitz","year":"2003","unstructured":"Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL . Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289: 1805\u20131812.","journal-title":"JAMA"},{"key":"BF0803084_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1210\/jc.2004-0263","volume":"90","author":"A Godoy-Matos","year":"2005","unstructured":"Godoy-Matos A, Carraro L, Vieira A, Oliviera A, Gues EP, Mattos L, Rangel C, Moreira RO, Coutimho W, Appolinario JC . Treatment of adolescents with sibutramine: a randomised, doule-blind, controlled study. J Clin Endocrinol Metab 2005; 90: 1460\u20131465.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"BF0803084_CR16","first-page":"S12","volume":"21","author":"R Guerciolini","year":"1997","unstructured":"Guerciolini R . Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl 3): S12\u2013S23.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0803084_CR17","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(98)22029-0","volume":"352","author":"L Sj\u00f6str\u00f6m","year":"1998","unstructured":"Sj\u00f6str\u00f6m L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M . Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 160\u2013161.","journal-title":"Lancet"},{"key":"BF0803084_CR18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1001\/archinte.160.9.1321","volume":"160","author":"SB Heymsfield","year":"2000","unstructured":"Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JPH, Sjostrom L . Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321\u20131326.","journal-title":"Arch Intern Med"},{"key":"BF0803084_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/oby.2000.8","volume":"8","author":"S R\u00f6ssner","year":"2000","unstructured":"R\u00f6ssner S, Sj\u00f6str\u00f6m L, Noack R, Meinders AE, Noseda G . Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49\u201361.","journal-title":"Obes Res"},{"key":"BF0803084_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/oby.2002.87","volume":"10","author":"JR McDuffie","year":"2002","unstructured":"McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA . Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642\u2013650.","journal-title":"Obes Res"},{"key":"BF0803084_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00431-004-1534-6","volume":"163","author":"B Ozkan","year":"2004","unstructured":"Ozkan B, Bereket A, Turan S, Keskin S . Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 738\u2013741.","journal-title":"Eur J Pediatr"},{"key":"BF0803084_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/j.1651-2227.2003.tb00596.x","volume":"92","author":"S Norgren","year":"2003","unstructured":"Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C . Orlistat treatment in obese prepubertal children: pilot study. Acta Paediatr 2003; 92: 666\u2013670.","journal-title":"Acta Paediatr"},{"issue":"Suppl 1","key":"BF0803084_CR23","first-page":"S195","volume":"28","author":"JP Chanoine","year":"2004","unstructured":"Chanoine JP, Hauptman J, Boldrin M, Smith D, Hampl S . Beneficial effects of orlistat on weight and body composition in obese adolescents. Int J Obes Relat Metab Disord 2004; 28 (Suppl 1): S195.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"BF0803084_CR24","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J . Effects of orlistat on weight and body composition in obese adolescents: a randomised controlled trial. JAMA 2005; 293: 2873\u20132883.","journal-title":"JAMA"},{"key":"BF0803084_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/oby.2004.151","volume":"12","author":"HE Bays","year":"2004","unstructured":"Bays HE . Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197\u20131211.","journal-title":"Obes Res"},{"key":"BF0803084_CR26","doi-asserted-by":"publisher","first-page":"167S","DOI":"10.1038\/oby.2004.284","volume":"12","author":"A Astrup","year":"2004","unstructured":"Astrup A, Toubro S . Topiramate: a new potential pharmacological treatment for obesity. Obes res 2004; 12: 167S\u2013173S.","journal-title":"Obes res"},{"key":"BF0803084_CR27","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"LF Van Gaal","year":"2005","unstructured":"Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabionid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1363\u20131364.","journal-title":"Lancet"},{"key":"BF0803084_CR28","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2337\/diab.45.11.1455","volume":"45","author":"JF Caro","year":"1996","unstructured":"Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV . Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455\u20131462.","journal-title":"Diabetes"},{"key":"BF0803084_CR29","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1021\/jm9802867","volume":"41","author":"J Dallongeville","year":"1998","unstructured":"Dallongeville J, Fruchart J-Ch, Auwerx J . Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. J Med Chem 1998; 41: 5337\u20135352.","journal-title":"J Med Chem"},{"key":"BF0803084_CR30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1056\/NEJM199909163411204","volume":"341","author":"IS Farooqi","year":"1999","unstructured":"Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S . Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879\u2013884.","journal-title":"N Engl J Med"},{"key":"BF0803084_CR31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/oby.2005.50","volume":"13","author":"L P\u00e9russe","year":"2005","unstructured":"P\u00e9russe L, Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Snyder EE, Bouchard C . The human obesity gene map: The 2004 update. Obes Res 2005; 13: 381\u2013490.","journal-title":"Obes Res"},{"key":"BF0803084_CR32","doi-asserted-by":"publisher","first-page":"4821","DOI":"10.1210\/jc.2004-0376","volume":"89","author":"WT Gibson","year":"2004","unstructured":"Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA . Congenital leptin deficiency due to homozygosity for the delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004; 89: 4821\u20134826.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF0803084_CR33","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","volume":"282","author":"SB Heymsfield","year":"1999","unstructured":"Heymsfield SB, Greenberg AS, Fujoka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCanish M . Recombinant leptin for weight loss in obese and lean adults. JAMA 1999; 282: 1568\u20131575.","journal-title":"JAMA"},{"key":"BF0803084_CR34","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1210\/jcem.85.11.6955","volume":"85","author":"CJ Hukshorn","year":"2000","unstructured":"Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, farid AR, Smith FJ, Campfield LA . Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003\u20134009.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF0803084_CR35","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1001\/jama.289.14.1826","volume":"289","author":"MP Ettinger","year":"2003","unstructured":"Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP . Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826\u20131832.","journal-title":"JAMA"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/0803084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803084","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/0803084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T07:35:05Z","timestamp":1684222505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/0803084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":35,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF0803084"],"URL":"https:\/\/doi.org\/10.1038\/sj.ijo.0803084","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}